These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia. Seddon AN; Chaim J; Akin O; Drill E; Michael AG; Adel N; Tallman MS Leuk Res; 2018 May; 68():48-50. PubMed ID: 29544131 [TBL] [Abstract][Full Text] [Related]
6. High-dose versus standard-dose daunorubicin in induction therapy for young patients with de novo acute myeloid leukaemia: a meta-analysis of randomised trials. Su L; Zhu X; Gao S; Li W; Liu X; Tan Y J Chemother; 2016 Apr; 28(2):123-8. PubMed ID: 27104964 [TBL] [Abstract][Full Text] [Related]
7. Role of daunorubicin in the induction therapy for adult acute myeloid leukemia. Usui N; Dobashi N; Kobayashi T; Yano S; Maki N; Asai O; Saito T; Yamaguchi Y; Watanabe H; Kato A; Ogihara A; Katori M; Nagamine M; Takei Y; Yamazaki H; Funakoshi S; Tajima N; Ogawa M; Kuraishi Y J Clin Oncol; 1998 Jun; 16(6):2086-92. PubMed ID: 9626208 [TBL] [Abstract][Full Text] [Related]
20. Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia. Choi EJ; Lee JH; Lee JH; Park HS; Ko SH; Hur EH; Moon J; Goo BK; Kim Y; Seol M; Lee YS; Kang YA; Jeon M; Woo JM; Lee KH Leuk Res; 2018 May; 68():51-56. PubMed ID: 29544132 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]